posted on 2021-01-28, 09:17authored byGiovanni E Ferreira, Andrew J McLachlan, Chung-Wei Christine Lin, Joshua R Zadro, Christina Abdel-Shaheed, Mary O'Keeffe, Chris G Maher
Objective:To investigate the efficacy and safety of antidepressants for back and osteoarthritis pain compared with placebo. Design: Systematic review and meta-analysis.
Data Sources: Medline, Embase, Cochrane Central Register of Controlled Trials, CINAHL, International Pharmaceutical Abstracts, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform from inception to 15 November and updated on 12 May 2020. Eligibility Criteria For Study Selection: Randomised
controlled trials comparing the efficacy or safety, or both of any antidepressant drug with
placebo (active or inert) in participants with low back or neck pain, sciatica, or hip or knee osteoarthritis. Data Extraction and Synthesis: Two independent reviewers extracted data. Pain and disability were primary outcomes. Pain and disability scores were converted to a scale of 0 (no pain or disability) to 100 (worst pain or disability). A random effects model was used to calculate weighted mean differences and 95% confidence intervals. Safety (any adverse event, serious adverse events, and proportion of participants who withdrew from trials owing to adverse events) was a secondary outcome. Risk of bias was assessed with the Cochrane Collaboration’s tool and certainty of evidence with the grading of recommendations assessment, development and evaluation (GRADE) framework.